Lilly Acquires Adverum for One-Time Eye Disease Gene Therapy
Eli Lilly announces acquisition of Adverum Biotechnologies for up to $12.47 per share to advance Ixo-vec, a promising one-time gene therapy for age-related macular degeneration.
/ 111 items
#LLY↓
Novo Nordisk Chairman and Six Directors Resign Amid Foundation Power Struggle
Novo Nordisk's chairman Helge Lund and six independent directors are stepping down after failing to reach agreement with majority shareholder over pace of board transformation as company faces market challenges.
WeightWatchers Partners with Amazon for GLP-1 Delivery
WeightWatchers partners with Amazon Pharmacy to offer easier access to GLP-1 weight-loss drugs like Wegovy and Zepbound, especially for customers in rural areas with faster delivery options.
Trump Vows Sharp Cut to Ozempic Price, Sending Novo Nordisk Shares Tumbling
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Novo Nordisk Acquires Akero Therapeutics for $5.2 Billion, Securing Key MASH Treatment EFX
Novo Nordisk has agreed to acquire clinical-stage Akero Therapeutics for up to $5.2 billion to integrate efruxifermin (EFX), a promising late-stage treatment for MASH, complementing Novo Nordisk's leadership in cardiometabolic disease.
Novo Nordisk Bets on Telehealth to Relaunch its Weight-Loss Dominance with "Wegovy-in-a-Pill"
Novo Nordisk is planning a strategic digital launch for its forthcoming obesity pill, targeting telehealth sites like Ro and WeightWatchers in early 2026 to recapture market share lost to rival Eli Lilly and combat the rise of copycat drugs.